Probiotics and Liver Disease

Sheth, Anish A.; García–Tsao, Guadalupe

doi:10.1097/mcg.0b013e318169c44e

Cited by 44 publications

(17 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The administration of probiotics has been shown to ameliorate hepatic encephalopathy and neutrophil dysfunction in patients with cirrhosis , which is in accordance with diverse beneficial effects observed from other type of manipulations of gut flora in patients with liver disease . The operative mechanisms of probiotics and their effects on other complications of liver disease such as the circulatory dysfunction remain, however, largely unknown . Here, we show that the oral administration of the probiotic VSL#3 preparation is associated with the amelioration of portal hypertension and systemic circulatory disturbances in patients with cirrhosis and ascites.…”

Section: Discussionsupporting

confidence: 74%

Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites

Rincón

Vaquero

Hernando

et al. 2014

Liver International

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 74%

Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites

Rincón

Vaquero

Hernando

et al. 2014

Liver International

View full text Add to dashboard Cite

show abstract

“…Indeed, this is mostly based on two major mechanisms, that is, the ability to augment the intestinal barrier function and to prevent the translocation of bacteria. 149 Both mechanisms represent the rationale for the use of probiotics to prevent major complications of liver cirrhosis such as the development of a hyperdynamic circulatory state or spontaneous bacterial peritonitis, with the former being the background for the establishment of portal hypertension. 150 While solid data …”

Section: Probiotics In Liver Diseases and Cancermentioning

confidence: 99%

Probiotics and immunity

et al. 2009

View full text Add to dashboard Cite

Probiotics are defi ned as live microorganisms that, when administered in adequate amounts, confer a health benefi t on the host, including the gastrointestinal tract. While this benefi cial effect was originally thought to stem from improvements in the intestinal microbial balance, there is now substantial evidence that probiotics can also provide benefi ts by modulating immune functions. In animal models, probiotic supplementation is able to provide protection from spontaneous and chemically induced colitis by downregulating infl ammatory cytokines or inducing regulatory mechanisms in a strain-specifi c manner. In animal models of allergen sensitization and murine models of asthma and allergic rhinitis, orally administered probiotics can straindependently decrease allergen-specifi c IgE production, in part by modulating systemic cytokine production. Certain probiotics have been shown to decrease airway hyperresponsiveness and infl ammation by inducing regulatory mechanisms. Promising results have been obtained with probiotics in the treatment of human infl ammatory diseases of the intestine and in the prevention and treatment of atopic eczema in neonates and infants. However, the fi ndings are too variable to allow fi rm conclusions as to the effectiveness of specifi c probiotics in these conditions.

show abstract

“…They can prevent bacterial translocation by decreasing intestinal bacterial overgrowth and improving intestinal barrier and immune disturbances2021. However, previous data on the prevention of bacterial translocation with probiotics in rodents treated with CCl 4 are contradictory.…”

mentioning

confidence: 99%

Fermented milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 reduces bacterial translocation in rats treated with carbon tetrachloride

Sánchez

Nieto

Vidal

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Probiotics can prevent pathological bacterial translocation by modulating intestinal microbiota and improving the gut barrier. The aim was to evaluate the effect of a fermented milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 on bacterial translocation in rats with carbon tetrachloride (CCl4)-induced cirrhosis. Sprague-Dawley rats treated with CCl4 were randomized into a probiotic group that received fermented milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 in drinking water or a water group that received water only. Laparotomy was performed one week after ascites development. We evaluated bacterial translocation, intestinal microbiota, the intestinal barrier and cytokines in mesenteric lymph nodes and serum. Bacterial translocation decreased and gut dysbiosis improved in the probiotic group compared to the water group. The ileal β-defensin-1 concentration was higher and ileal malondialdehyde levels were lower in the probiotic group than in water group. There were no differences between groups in serum cytokines but TNF-α levels in mesenteric lymph nodes were lower in the probiotic group than in the water group. Fermented milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 decreases bacterial translocation, gut dysbiosis and ileal oxidative damage and increases ileal β-defensin-1 expression in rats treated with CCl4, suggesting an improvement in the intestinal barrier integrity.

show abstract

Probiotics and Liver Disease

Cited by 44 publications

References 49 publications

Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites

Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites

Probiotics and immunity

Fermented milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 reduces bacterial translocation in rats treated with carbon tetrachloride

Contact Info

Product

Resources

About